FOR SCIENTIFIC RESEARCH ONLY, NOT FOR HUMAN OR VETERINARY CONSUMPTION

FOR SCIENTIFIC RESEARCH ONLY, NOT FOR HUMAN OR VETERINARY CONSUMPTION

TB-500 – 10mg
TB-500 – 10mg
TB-500 – 10mg
TB-500 – 10mg

TB-500 – 10mg

GBP 22.50

Scientific data for TB-500 (Ac-LKKTETQ) identifies it as a synthetic heptapeptide derived from the active site (amino acids 17–23) of the naturally occurring protein Thymosin Beta-4 (Tβ4). While it is widely marketed for tissue repair, it is currently classified by the U.S. FDA as a Category 2 bulk drug substance, meaning it has significant safety concerns and is not approved for human use.

Bulk deal
Quantity Discount Discounted price
5 - 9 10% GBP 20.25
10 + 20% GBP 18.00

Description

Molecular Characteristics

Structure: A synthetic analog of the N-terminal acetylated 17–23 fragment of Tβ4.
Molecular Formula: C38H68N10O14
Molecular Weight: Approximately 889.02 Da.
Sequence: Ac-LKKTETQ.

Biological Mechanisms

Preclinical research suggests TB-500 mimics several functions of its parent molecule, Tβ4, primarily through actin regulation:
Actin Sequestration: Binds to G-actin monomers, preventing their polymerization into F-actin. This increases cellular motility, allowing repair cells to migrate to injury sites.
Angiogenesis: Promotes the formation of new blood vessels by upregulating VEGF (Vascular Endothelial Growth Factor) expression.
Anti-inflammatory Effects: Reduces pro-inflammatory cytokines like TNF-α , IL-1β, and IL-6.
Metabolic Insights: Research published in 2024 suggests that TB-500 itself may not be the primary active agent for wound healing; instead, its metabolite Ac-LKKTE showed significant activity in fibroblast experiments, while the parent form did not.

Evidence for Efficacy (Preclinical)

Most data comes from animal models (mice, rats, and horses):
Wound Healing: Accelerated closure rates by 40–55% in diabetic and aged mouse models.
Tendon/Ligament Repair: Increased tensile strength and improved functional recovery in rat Achilles tendon and rotator cuff models.
Cardiovascular: Reduced infarct size and improved left ventricular function in mouse coronary ligation models.

Safety and Regulatory Status

Human Data: There are zero completed large-scale human clinical trials specifically for TB-500. Most human-facing data is extrapolated from Thymosin Beta-4 trials, which showed safety in Phase II for cardiac and ocular use but are not identical to TB-500.
Banned Substance: Prohibited by the World Anti-Doping Agency (WADA) under category S0 (Non-Approved Substances).
Risks: Potential concerns include oncogenic risk (angiogenesis could theoretically promote tumor growth), immune sensitization, and product quality issues (contaminants like endotoxins) in the unregulated market.

Are you researching TB-500 for musculoskeletal recovery or for regulatory compliance in professional sports?

Reviews

There are no reviews yet.

Be the first to review “TB-500 – 10mg”

Your email address will not be published. Required fields are marked *

Certificate of Analysis

You can view the lab report for this product below.

All products on this site are for laboratory research only. Not for human or animal consumption. You must be 18+ to buy.